Dr Samar Al-Behaisi
Chief Medical Officer and Vice President of Medical Affairs
Samar Al-Behaisi, MD, PhD joined the pharmaceuticals industry more than 20 years ago, after completing her general medical studies and post graduate scholarship in Experimental Cancer Research focusing on chemotherapeutics in oncology practice. She served in various roles leading early phase clinical research projects before finding her passion in medical affairs. Her last industry role was as the European medical lead for the lymphoma franchise at Takeda Pharmaceuticals, who at the time was transitioning from primary health to specialty care. That role included being actively involved in building the European Oncology Medical Affairs organisation and emphasising the importance of cross-functional team work in addition to launching the first Antibody-drug-conjugate (ADC) in Europe. Before that, she was contributing to the success of various launches at Genyzme, GSK and Novartis Oncology, both at European as well as national levels. Other than lymphoma, she has worked in multiple disease areas such as leukemias (including paediatric), multiple myeloma, hematopoietic stem cell transplantation (HSCT), breast and lung cancer.
Samar is also a certified expert in pharmaco-economics & health policies. Her passion for oncology has been the main driver of her work and interests, hence the work on Orphan Drug Payors’ negotiation techniques using a newly approved treatment for a refractory and/or relapsed paediatric malignancy as a base case. She has also won industry awards in recognition of her efforts and dedication to her assignments.
To view Samar Al-Behaisi’s LinkedIn profile, please click here.